Revue des maladies respiratoires最新文献

{"title":"[Non-small cell lung cancer in adults under 40 years of age].","authors":"M Lemaire, V Durieux, A-P Meert, T Berghmans","doi":"10.1016/j.rmr.2024.09.005","DOIUrl":"https://doi.org/10.1016/j.rmr.2024.09.005","url":null,"abstract":"<p><strong>Introduction: </strong>Non-small cell lung cancers (NSCLC) are the most common lung cancers, withpeak incidence at 65years of age. These cancers rarely occur before the age of 40.</p><p><strong>Methods: </strong>Based on an illustrative clinical case, a systematic review of the literature was conducted to study the epidemiological, clinical, histological, and biological characteristics of NSCLC in adults under 40years of age. Two equations were developed to search for articles on Medline and Scopus.</p><p><strong>Results: </strong>Sixty-five articles were included in the review; 1.7% of patients were under 40years old, 50.7% were women, 66.7% presented adenocarcinoma, 51.9% were diagnosed at stage IV, 75% were non-smokers, 39.9% were exposed to other toxins, 33% had an EGFR mutation, 6.6% had a KRAS mutation, 25% had an ALK translocation, 73.7% were symptomatic, and over 75% had PS<2.</p><p><strong>Conclusion: </strong>NSCLC in patients under 40years of age presents characteristics different from those in older patients. Various factors are implicated, one example being lower exposure to tobacco, and they can influence the distribution of histological subtypes and the frequency of mutations.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Obstructive apnea hypopnea syndrome in pregnancy].","authors":"V Bironneau","doi":"10.1016/j.rmr.2024.10.001","DOIUrl":"https://doi.org/10.1016/j.rmr.2024.10.001","url":null,"abstract":"<p><p>Obstructive sleep apnea hypopnea syndrome (OSA) in pregnant women is an under-diagnosed but common condition, due to the numerous physiological changes favoring upper airway collapse. Risk factors such as significant weight gain during the 1st trimester, maternal age and parity should be systematically investigated. Diagnosis is made by sleep recording. OSA can lead to maternal and fetal complications (gestational diabetes, eclampsia, intrauterine growth restriction, prematurity…) during pregnancy, delivery and the post-partum period. It is therefore essential to treat apneic patients as early as possible in pregnancy. Treatment includes hygienic and dietary measures, as well as continuous positive airway pressure (CPAP). Systematic post-partum follow-up with polygraphic monitoring should be proposed.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142507072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The impact of maternal smoking during pregnancy on respiratory disease in children].","authors":"H Petat, J Mazenq","doi":"10.1016/j.rmr.2024.08.005","DOIUrl":"10.1016/j.rmr.2024.08.005","url":null,"abstract":"<p><p>Among the causes of abnormal fetal lung development, active and environmental maternal smoking represents a major potential target in preventive medicine. Prevalence of smoking among women, particularly during pregnancy, varies across the different regions of the world. We reviewed the literature on the repercussions of maternal smoking on the lungs of the fetus and the neonate. One of the main consequences is prematurity, leading to pulmonary bronchodysplasia followed by respiratory infections, which particularly affect young children. In the medium- and long-term, smoking in utero leads to asthma and allergies, and is suspected to be associated with impaired respiratory function in children and teenagers. We also report on the potential effects of e-cigarettes, which represent an emerging threat to children's respiratory health.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[An impressive chest swelling].","authors":"F Vandenbos","doi":"10.1016/j.rmr.2024.09.003","DOIUrl":"10.1016/j.rmr.2024.09.003","url":null,"abstract":"","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"L’oscillométrie respiratoire : théorie et applications cliniques","authors":"","doi":"10.1016/j.rmr.2024.08.002","DOIUrl":"10.1016/j.rmr.2024.08.002","url":null,"abstract":"<div><div>L’oscillométrie permet de mesurer les propriétés mécaniques du système respiratoire. Les mesures d’oscillométrie sont réalisées en respiration spontanée et ne nécessitent pas de manœuvres respiratoires forcées ou la coopération active du sujet. Cette technique complémentaire aux techniques d’explorations fonctionnelles respiratoires classiques, offre de nouvelles possibilités pour l’exploration de la fonction respiratoire, le diagnostic et le suivie des maladies respiratoires, et l’évaluation de la réponse au traitement. Cette revue vise à décrire les bases théoriques et la méthodologie pratique de l’oscillométrie. Elle décrit les questions concernant son utilité clinique où les données scientifiques sont manquantes ou en pleine évolution, et donne des exemples de son application en investigation et en clinique.</div></div><div><div>Oscillometry measures the mechanical properties of the respiratory system. As they are carried out during spontaneous breathing, oscillometry measurements do not require forced breathing maneuvers or the patient's active cooperation. The technique is complementary to conventional pulmonary function testing methods for the investigation of respiratory function, diagnosis and monitoring of respiratory diseases, and assessment of response to treatment. The present review aims to describe the theoretical foundations and practical methodology of oscillometry. It describes the gaps in scientific evidence regarding its clinical utility, and provides examples of current research and clinical applications.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sommaire","authors":"","doi":"10.1016/S0761-8425(24)00283-3","DOIUrl":"10.1016/S0761-8425(24)00283-3","url":null,"abstract":"","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CBNPC sans addictions oncogéniques métastatique cérébral d’emblée : place de l’immunothérapie","authors":"","doi":"10.1016/j.rmr.2024.05.004","DOIUrl":"10.1016/j.rmr.2024.05.004","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Environ 30 % des patients atteints d’un cancer pulmonaire non à petites cellules (CBNPC) de stade avancé ont des métastases cérébrales au diagnostic. L’immunothérapie, seule ou associée à la chimiothérapie, est le standard de 1&lt;sup&gt;re&lt;/sup&gt; ligne, en l’absence d’addiction oncogénique. L’objectif de cette revue est de discuter les données disponibles avec l’immunothérapie chez ces patients, ainsi que la place de la radiothérapie.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;État des connaissances&lt;/h3&gt;&lt;div&gt;Dans les études ayant validé l’immunothérapie, les patients atteints de métastases cérébrales semblaient avoir le même bénéfice de survie globale avec l’immunothérapie que les autres. Cependant, ces patients étaient sélectionnés, avec des métastases cérébrales pré-traitées et stables. Plusieurs études rétrospectives et deux études prospectives non comparatives spécifiquement dans cette population suggèrent une efficacité intracérébrale de l’immunothérapie.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Perspectives&lt;/h3&gt;&lt;div&gt;La place de la radiothérapie cérébrale reste débattu, sans étude randomisée à ce jour ayant évaluée l’ajout d’une radiothérapie cérébrale à l’immunothérapie en 1ère ligne. Une méta-analyse récente montrait une augmentation de la réponse intracérébrale lorsque la radiothérapie était ajoutée à l’immunothérapie.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Les données disponibles suggèrent un bénéfice de l’immunothérapie en 1&lt;sup&gt;re&lt;/sup&gt; ligne, seule ou combinée à la chimiothérapie, chez ces patients. Ces données sont toutefois issues d’études rétrospectives, non randomisées et de faibles effectifs.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Up to 30% patients newly diagnosed with advanced non-small cell lung cancer (NSCLC) present with brain metastases. In the absence of oncogenic addiction, first-line immunotherapy, alone or in combination with chemotherapy, is the current standard of care. This review aims to synthesize the available data regarding the efficacy of immunotherapy in these patients, and to discuss the possibility of its being coordinated with local treatments such as radiotherapy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;State of the art&lt;/h3&gt;&lt;div&gt;NSCLC patients with brain metastases appear to have survival benefits with immunotherapy similar to those of NSCLC patients without brain metastases. However, this finding is based on mainly prospective studies having included highly selected patients with pre-treated and stable brain metastases. Several retrospective studies and two prospective single-arm studies have confirmed the intracranial efficacy of immunotherapy, either alone or in combination with chemotherapy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Perspectives&lt;/h3&gt;&lt;div&gt;The indications and optimal timing for cerebral radiotherapy remain subjects of debate. To date, there exists no randomized study assessing the addition of brain radiotherapy to first-line immunotherapy. That said, a recent meta-analysis showed increased intracerebral response when radiotherapy complemented i","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Méthotrexate à faible dose : indications et effets secondaires, en particulier en cas de pneumopathie interstitielle diffuse","authors":"","doi":"10.1016/j.rmr.2024.06.008","DOIUrl":"10.1016/j.rmr.2024.06.008","url":null,"abstract":"<div><h3>Introduction</h3><div>Le méthotrexate (MTX) est un antagoniste des folates utilisé comme immunosuppresseur dans de nombreuses pathologies, notamment la polyarthrite rhumatoïde (PR). Le MTX à faible dose (MTX-LD) est associé à un risque de toxicité hématologique, hépatique, gastro-intestinale et pulmonaire, qui a pu limiter son utilisation.</div></div><div><h3>État des connaissances</h3><div>Dans la PR, des données provenant de cohortes rétrospectives rapportaient un possible sur-risque de toxicité du méthotrexate en cas de pneumopathie interstitielle diffuse (PID) sous-jacente. Des études récentes, prospectives et rétrospectives multicentriques, ne retrouvent pas ce surrisque et sont rassurantes quant à la possibilité de prescrire du MTX-LD en cas de PID associée à une PR (PR-PID). Le MTX-LD pourrait même avoir un rôle protecteur sur l’évolution d’une PR-PID.</div></div><div><h3>Perspectives et conclusions</h3><div>Compte-tenu de ces résultats récents, les recommandations actuelles sont de ne pas retarder l’introduction de MTX chez des patients présentant une PR à risque de développer une PID ou en présence d’une PR-PID avec retentissement respiratoire léger à modéré.</div></div><div><h3>Introduction</h3><div>Methotrexate (MTX) is a folate antagonist used as an immunosuppressant in a number of conditions, including rheumatoid arthritis (RA). Low-dose MTX (MTX-LD) is associated with a risk of haematological, hepatic, gastrointestinal and pulmonary toxicity, which may up until now have limited its use.</div></div><div><h3>State of the art</h3><div>In RA, data from retrospective cohorts have reported a possible excess risk of methotrexate toxicity in cases of underlying interstitial lung disease (ILD). However, recent prospective and retrospective multicentre studies have found no such increased risk, and have reassuringly concluded that MTX-LD can be prescribed in cases of RA-associated ILD (RA-ILD).</div></div><div><h3>Perspectives and conclusions</h3><div>Current recommendations are not to delay the introduction of MTX in patients with RA at risk of developing ILD or in the presence of RA-ILD with mild to moderate respiratory impairment.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tuberculose pré- et ultrarésistante à Libreville, Gabon","authors":"","doi":"10.1016/j.rmr.2024.06.011","DOIUrl":"10.1016/j.rmr.2024.06.011","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Très peu de travaux abordent la tuberculose (TB) pré- et ultrarésistante.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;Présenter l’épidémiologie de la tuberculose pré- et ultrarésistante et le devenir des patients atteints de TB multirésistante.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;Il s’agit d’une étude rétrospective portant sur la période d’activités du centre antituberculeux de Nkembo de 2019 à 2022.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Parmi les 15 patients éligibles, 11 (73,3 %) étaient pré-ultrarésistants et 4 (26,7 %) ultrarésistants. Trois (20,0 %) patients avaient une co-infection TB/VIH. L’échantillon était constitué de 7 (46,7 %) hommes et 8 (53,3 %) femmes soit un sex-ratio de 0,87. L’âge moyen était de 35,6 ans, la médiane 34 ans avec des extrêmes de 23 et 60 ans. Dans 53,3 % (&lt;em&gt;n&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;8), il s’agissait de nouveaux cas de tuberculose pré-ultrarésistant ou ultrarésistant. La majorité des patients (60 %; &lt;em&gt;n&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;9) provenait des quartiers précaires avec une forte promiscuité. Le taux de succès thérapeutique parmi les tuberculeux pré-ultrarésistants était de 36,4 % (&lt;em&gt;n&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;4) versus 50,0 % (&lt;em&gt;n&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;2) parmi les patients tuberculeux ultrarésistants. La mortalité déclarée était de 33,3 % (&lt;em&gt;n&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;5) durant le traitement. Tous les décès sont apparus avant la fin du premier trimestre.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;La fréquence élevée de la tuberculose pré-ultrarésistante et ultrarésistante primaire illustre la problématique de la résistance aux antituberculeux et soulèvent le rôle du dépistage des cas contacts et d’un traitement précoce.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Very few studies have been devoted to extensively drug-resistant (XDR) strains of &lt;em&gt;Mycobacterium tuberculosis&lt;/em&gt; (TB) in Gabon.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Aim&lt;/h3&gt;&lt;div&gt;The aim of the present study is to present the epidemiology of pre-XDR and XDR TB and the evolution over time of patients with multidrug-resistant TB.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This retrospective study covered the activities from 2019 to 2022 of the Nkembo anti-tuberculosis center.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Fifteen patients were eligible, including 11 (73.3%) pre-XDR patients and 4 (26.7%) XDR-TB patients. Three (20.0%) patients had HIV/TB co-infection. The sample consisted of 7 men (46.7%) and 8 women (53.3%), a sex ratio (M/F) of 0.87. The average age was 35.6 years, and the median 34 years, with extremes of 23 and 60 years. Eight patients (53.3%) represented new cases of pre-XDR or XDR-TB tuberculosis. The majority (60%; &lt;em&gt;n&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;9) came from deprived neighborhoods with widespread promiscuity. The therapeutic success rate among pre-XDR patients was 4 (36.4%) versus 2 (50.0%) among XDR-TB patients. Reported mortality occurred 5 (33.3%) patients during treatment, including 3 pre-XDR and 2 XDR-TB patients. In all cases, they died","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142047146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Get up, stand up ! Ce que les tests de lever de chaise nous disent de l’insuffisance respiratoire","authors":"","doi":"10.1016/j.rmr.2024.06.003","DOIUrl":"10.1016/j.rmr.2024.06.003","url":null,"abstract":"<div><div>Les pathologies associées à une insuffisance respiratoire chronique impactent négativement la qualité et l’espérance de vie notamment par le biais d’une réduction des capacités fonctionnelles des patients. L’évaluation de l’équilibre, de la coordination, de la force et de l’endurance musculaires ainsi que de la tolérance à l’effort constituent donc une part importante de l’évaluation des patients insuffisants respiratoires. La mise en œuvre de cette évaluation peut être facilitée par l’utilisation d’outils simples comme les tests de lever de chaise (TLC). Cette revue présente les principaux TLC décrits et utilisables en pratique courante. Elle a vocation à permettre de comprendre pour chacun d’eux ce qu’il apporte au clinicien, et dans quelle mesure et à quelles fins ces tests peuvent être intégrés à un bilan de pneumologie et/ou de rééducation respiratoire de routine. Par leur caractère éminemment fonctionnel, ces tests pourraient contribuer à faciliter l’identification des indications et/ou des effets de la réadaptation respiratoire.</div></div><div><div>Diseases associated with chronic respiratory failure have a negative impact on quality of life and life expectancy, notably through a reduction in patients’ functional capacity. Assessing balance, coordination, muscular strength and endurance, as well as exercise tolerance, is therefore an important component of the evaluation of individuals with chronic respiratory failure. This evaluation can be made easier by using simple tools such as sit-to-stand tests. This review presents the main sit-to-stand tests that have been described and that can be used in everyday practice. The aim is to provide information to the clinician on the contribution of each test, and to identify the extent to which and the purpose for which these tests can be incorporated into a routine pulmonology and/or respiratory rehabilitation evaluation. Because of their inherently functional nature, these tests could help to identify the indications and/or the effects of respiratory rehabilitation.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}